PRDS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PRDS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Pardes Biosciences's other current assets for the quarter that ended in Jun. 2023 was $4.11 Mil.
Pardes Biosciences's quarterly other current assets increased from Dec. 2022 ($3.06 Mil) to Mar. 2023 ($3.91 Mil) and increased from Mar. 2023 ($3.91 Mil) to Jun. 2023 ($4.11Mil).
Pardes Biosciences's annual other current assets increased from Dec. 2020 ($0.19 Mil) to Dec. 2021 ($6.58 Mil) declined from Dec. 2021 ($6.58 Mil) to Dec. 2022 ($3.06 Mil).
The historical data trend for Pardes Biosciences's Other Current Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pardes Biosciences Annual Data | |||||||
Trend | Dec20 | Dec21 | Dec22 | ||||
Other Current Assets | 0.19 | 6.58 | 3.06 |
Pardes Biosciences Quarterly Data | ||||||||||
Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | |
Other Current Assets | Get a 7-Day Free Trial | 5.25 | 4.99 | 3.06 | 3.91 | 4.11 |
Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:
The assets grouped under other current assets are most commonly:
Some companies can and do choose to report each of these items separately.
Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.
Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.
Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.
Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.
There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.
At most companies, other current assets are a small and unimportant part of the total balance sheet.
Thank you for viewing the detailed overview of Pardes Biosciences's Other Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Fs Development Holdings Ii, Llc | 10 percent owner | 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111 |
Foresite Capital Opportunity Fund V, L.p. | 10 percent owner | 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111 |
Foresite Capital Fund V, L.p. | 10 percent owner | 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111 |
Sean P. Brusky | officer: Chief Commercial Officer | C/O PARDES BIOSCIENCES, INC., 2173 SALK AVE., SUITE 250, PMB#052, CARLSBAD CA 92008 |
Thomas G Wiggans | director, officer: Chief Executive Officer | |
Foresite Capital Management V, Llc | 10 percent owner | 900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939 |
Pottage John C Jr | director | ACHILLION PHARMACEUTICALS, 300 GEORGE STREET, NEW HAVEN CT 06511 |
Alsup Laurie Smaldone | director | 190 WOOSAMONSA RD, PENNINGTON NJ 08534 |
Heidi Henson | officer: Chief Financial Officer | 2173 SALK AVENUE, SUITE 250, PMB#052, CARLSBAD CA 92008 |
J Jay Lobell | director | 365 W END AVE, APARTMENT 10A, NEW YORK NY 10024 |
Brian Philippe Tinmouth | officer: Chief Business & Strategy Ofcr | 1 EVERTRUST PLAZA, 13TH FLOOR, JERSEY CITY NJ 07302-6548 |
Brian Kearney | officer: Chief Development Officer | C/O PARDES BIOSCIENCES, INC., 2173 SALK AVE., SUITE 250, PMB#052, CARLSBAD CA 92008 |
Laura Hamill | director | 333 LAKESIDE DRIVE, FOSTER CITY CA 94404 |
Lee D Arnold | officer: Chief Scientific Officer | C/O ASSEMBLY BIOSCIENCES, INC., 99 HUDSON STREET, 5TH FLOOR, NEW YORK NY 10013 |
Uri A Lopatin | director, officer: President and CEO | C/O ASSEMBLY BIOSCIENCES, INC., 99 HUDSON STREET, 5TH FLOOR, NEW YORK NY 10013 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 07-09-2022
By Business Wire • 08-28-2023
By PRNewswire • 08-01-2023
By Marketwired • 07-10-2023
By Value_Insider Value_Insider • 11-01-2022
By Value_Insider Value_Insider • 11-07-2022
By Marketwired • 07-21-2023
By Marketwired • 08-14-2023
By Marketwired • 06-24-2023
By PurpleRose PurpleRose • 08-15-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.